From rational design to serendipity: Discovery of novel thiosemicarbazones as potent trypanocidal compounds
作者:Saulo Fehelberg Pinto Braga、Viviane Corrêa Santos、Rafael Pinto Vieira、Elany Barbosa da Silva、Ludovica Monti、Susann H. Krake、Pablo D.G. Martinez、Luiz Carlos Dias、Conor R. Caffrey、Jair L. Siqueira-Neto、Renata Barbosa de Oliveira、Rafaela Salgado Ferreira
DOI:10.1016/j.ejmech.2022.114876
日期:2022.12
Here, we describe the design and synthesis of derivatives of our lead compound. The new thiosemicarbazone derivatives showed potency in the nanomolar concentration range against the two enzymes, but they were later characterized as aggregators. Nevertheless, the thiosemicarbazone derivatives showed promising antiparasitic activities against T. b. brucei (EC50 13–49.7 μM) and T. cruzi (EC50 0.027–0.59 μM)
恰加斯病是由病原体克氏锥虫引起的主要公共卫生问题,估计有 6-7 百万人受到感染,7000 万人面临感染风险。T. brucei gambiense和T. brucei rhodesiense是导致非洲人类锥虫病的相关寄生虫的两个亚种,这是一种被忽视的热带疾病,也有数百万人面临感染风险。这两种疾病的药物治疗都存在疗效低下、副作用或耐药性等问题。最近,我们报道了 cruzain(IC 50 26 μM ,K i 3 μM)和Tbr CatL(IC 5050 μM),两种半胱氨酸蛋白酶被认为是锥虫病有希望的药物靶点。在这里,我们描述了先导化合物衍生物的设计和合成。新的缩氨基硫脲衍生物在纳摩尔浓度范围内显示出对这两种酶的效力,但它们后来被表征为聚集剂。尽管如此,缩氨基硫脲衍生物显示出对T. b.有希望的抗寄生虫活性。brucei (EC 50 13–49.7 μM) 和T. cruzi (EC 50